Summit Therapeutics SMMT Proceeds from maturities of short-term investments

Proceeds from maturities of short-term investments at other companies

FabrinetFN

$112.11M+180%

Cboe Global MarketsCBOE

$1.5M-67.4%

CF IndustriesCF

$2.25M—

Kimberly-ClarkKMB

$83M-55.4%

American TowerAMT

$0-100%

Hyatt HotelsH

$186M+38.8%

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's proceeds from maturities of short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's proceeds from maturities of short-term investments?: Summit Therapeutics (SMMT) reported proceeds from maturities of short-term investments of $177.29M in Q1 2026.
How has Summit Therapeutics's proceeds from maturities of short-term investments changed year-over-year?: Summit Therapeutics's proceeds from maturities of short-term investments increased by 10.4% year-over-year, from $160.53M to $177.29M.